GX1 genXone NewConnect · annual · publ. April 23, 2026

FY 2025 report

Mała spółka biotechnologiczna (sekwencjonowanie nanoporowe) z przychodami 2,3 mln zł (+31% r/r) i stratą netto 2,6 mln zł (2024: 3,9 mln zł).

Sentiment

Cautious No guidance change

Website

GX1 FY 2025 report

Revenue

2,343,543 PLN

— YoY

Net income

-2,639,646 PLN

— YoY

EBITDA

-1,712,332 PLN

— YoY

FCF

-2,469,443 PLN

— YoY

Summary

Investment thesis

Kluczowy partner i największy akcjonariusz (40,3%) to Diagnostyka S.A. — dla niego powstają testy HPV i mikrobioty, co zmniejsza ryzyko komercjalizacji, ale zwiększa zależność.
Brak zadłużenia, gotówka 3,36 mln zł wystarcza przy obecnym tempie spalania (OCF -2,4 mln zł) na ok. 1,4 roku; kapitał zapasowy systematycznie topnieje na pokrycie strat.
Aktywa to w połowie skapitalizowane prace rozwojowe (4,54 mln zł, 50,6% sumy bilansowej), w 2025 r. odpisano 0,52 mln zł dwóch projektów B+R — ryzyko dalszych odpisów.
Po dniu bilansowym uzgodniono spłatę wcześniej odpisanej należności od gMendel ApS (110 tys. EUR), co może poprawić wynik przyszłych okresów.

Read the full analysis

Financial data is open to everyone. The full analysis — management verdict, commentary, risks, and the full narrative — is available after you sign up or log in.

Financials

BETA

FY 2025

GX1 · FY 2025

Metric	FY 2025	FY 2024	Δ YoY	Value type	Segment	Conf.

Revenue	2,343,543	—	—	reported	—	1.00
EBITDA	-1,712,332	—	—	derived	—	0.70
EBIT	-2,804,069	—	—	reported	—	1.00
EBT	-2,637,948	—	—	reported	—	1.00
Net income	-2,639,646	—	—	reported	—	1.00
EPS (basic)	-0.8	—	—	reported	—	0.70
D&A	1,091,736	—	—	reported	—	1.00
Interest expense	8,364	—	—	reported	—	1.00
Income tax	1,698	—	—	reported	—	1.00
Shares (basic) (units)	3,304,820	—	—	reported	—	1.00

EBITDA margin	-73.07%	—	—	derived	—	0.70
EBIT margin	-119.65%	—	—	derived	—	0.70
EBT margin	-112.56%	—	—	derived	—	0.70
Net margin	-112.63%	—	—	derived	—	0.70
D&A margin	46.58%	—	—	derived	—	0.70

Cash	3,357,888	—	—	reported	—	1.00
Total debt	0	—	—	reported	—	1.00
Net debt	-3,357,888	—	—	reported	—	0.80
Equity	8,410,326	—	—	reported	—	1.00
Total assets	8,963,042	—	—	reported	—	1.00
Working capital	3,686,096	—	—	derived	—	0.70
Current assets	4,116,762	—	—	reported	—	1.00
Current liabilities	430,666	—	—	reported	—	1.00
Inventory	180,611	—	—	reported	—	1.00
Trade receivables	475,113	—	—	reported	—	0.90
Trade payables	73,568	—	—	reported	—	1.00
Goodwill	4,561,070	—	—	reported	—	1.00
Tangible equity	3,849,256	—	—	derived	—	0.70

CFO	-2,389,036	—	—	reported	—	1.00
CapEx	80,407	—	—	reported	—	0.80
FCF	-2,469,443	—	—	derived	—	0.70

ROE	-27.13%	—	—	derived	—	0.70
ROA	-25.56%	—	—	derived	—	0.70
ROCE	-32.86%	—	—	derived	—	0.70

Current ratio	9.56x	—	—	derived	—	0.70
Quick ratio	9.14x	—	—	derived	—	0.70
Cash ratio	7.8x	—	—	derived	—	0.70

Debt / equity	0x	—	—	derived	—	0.70
Debt / assets	0x	—	—	derived	—	0.70
Net debt / equity	-0.4x	—	—	derived	—	0.70

Revenue growth (YoY)	31.07%	—	—	derived	—	0.70
EBITDA growth (YoY)	41.17%	—	—	derived	—	0.70
EBIT growth (YoY)	34.24%	—	—	derived	—	0.70
Net income growth (YoY)	32.78%	—	—	derived	—	0.70
EPS growth (YoY)	32.78%	—	—	derived	—	0.70
EBITDA margin Δ (YoY)	89.71 pp	—	—	derived	—	0.70
EBIT margin Δ (YoY)	118.83 pp	—	—	derived	—	0.70
Net margin Δ (YoY)	106.97 pp	—	—	derived	—	0.70

FY 2025 · Δ YoY

Revenue

2,343,543 —

FY 2024: —

EBITDA

-1,712,332 —

FY 2024: —

EBIT

-2,804,069 —

FY 2024: —

EBT

-2,637,948 —

FY 2024: —

Net income

-2,639,646 —

FY 2024: —

EPS (basic)

-0.8 —

FY 2024: —

D&A

1,091,736 —

FY 2024: —

Interest expense

8,364 —

FY 2024: —

Income tax

1,698 —

FY 2024: —

Shares (basic) (units)

3,304,820 —

FY 2024: —

EBITDA margin

-73.07% —

FY 2024: —

EBIT margin

-119.65% —

FY 2024: —

EBT margin

-112.56% —

FY 2024: —

Net margin

-112.63% —

FY 2024: —

D&A margin

46.58% —

FY 2024: —

Cash

3,357,888 —

FY 2024: —

Total debt

0 —

FY 2024: —

Net debt

-3,357,888 —

FY 2024: —

Equity

8,410,326 —

FY 2024: —

Total assets

8,963,042 —

FY 2024: —

Working capital

3,686,096 —

FY 2024: —

Current assets

4,116,762 —

FY 2024: —

Current liabilities

430,666 —

FY 2024: —

Inventory

180,611 —

FY 2024: —

Trade receivables

475,113 —

FY 2024: —

Trade payables

73,568 —

FY 2024: —

Goodwill

4,561,070 —

FY 2024: —

Tangible equity

3,849,256 —

FY 2024: —

CFO

-2,389,036 —

FY 2024: —

CapEx

80,407 —

FY 2024: —

FCF

-2,469,443 —

FY 2024: —

ROE

-27.13% —

FY 2024: —

ROA

-25.56% —

FY 2024: —

ROCE

-32.86% —

FY 2024: —

Current ratio

9.56x —

FY 2024: —

Quick ratio

9.14x —

FY 2024: —

Cash ratio

7.8x —

FY 2024: —

Debt / equity

0x —

FY 2024: —

Debt / assets

0x —

FY 2024: —

Net debt / equity

-0.4x —

FY 2024: —

Revenue growth (YoY)

31.07% —

FY 2024: —

EBITDA growth (YoY)

41.17% —

FY 2024: —

EBIT growth (YoY)

34.24% —

FY 2024: —

Net income growth (YoY)

32.78% —

FY 2024: —

EPS growth (YoY)

32.78% —

FY 2024: —

EBITDA margin Δ (YoY)

89.71 pp —

FY 2024: —

EBIT margin Δ (YoY)

118.83 pp —

FY 2024: —

Net margin Δ (YoY)

106.97 pp —

FY 2024: —